A. Railkar

发表

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

A. Polonskaia, C. Lukacs, Hongmao Sun, 2013, Bioorganic & medicinal chemistry letters.

Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.

D. Davis, A. Railkar, Amy D. Fung, 2014, Journal of medicinal chemistry.

Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.

Yi Chen, K. Luk, A. Railkar, 2006, Bioorganic & medicinal chemistry letters.

Comparison of Various Injectable Protein-Loaded Biodegradable Poly(Lactide-co-glycolide) (PLGA) Devices: In-Situ-Formed Implant Versus In-Situ-Formed Microspheres Versus Isolated Microspheres

A. Railkar, R. A. Jain, C. Rhodes, 2000, Pharmaceutical development and technology.

In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver.

Ying Peng, Stephen Fowler, Neil Parrott, 2013, Molecular pharmaceutics.

Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).

A. Railkar, J. Grippo, F. Matschinsky, 2010, Journal of medicinal chemistry.

Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.

A. Railkar, A. Sidduri, J. Lou, 2013, Bioorganic & medicinal chemistry letters.

Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.

A. Railkar, A. Sidduri, J. Lou, 2013, Bioorganic & medicinal chemistry letters.

Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.

C. Lukacs, C. Janson, A. Railkar, 2012, ACS medicinal chemistry letters.

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.

Johannes C. Hermann, C. Lukacs, A. Kuglstatter, 2014, Journal of medicinal chemistry.

In Vitro Characterization of Polymeric Membrane used for Controlled Release Application

A. Railkar, N. Shah, W. Phuapradit, 1995 .

Studies on an Oral Iron Chelator: 1,2‐Dimethyl‐3‐hydroxy‐pyrid‐4‐one (DMHP). Mechanism of Intestinal Absorption in Rabbits

A. Railkar, R. Camp, Y. Rahman, 1993, The Journal of pharmacy and pharmacology.

RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation.

K. Luk, A. Railkar, B. Higgins, 2005, Bioorganic & Medicinal Chemistry.

Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models

N. Fotouhi, A. Railkar, D. Heimbrook, 2010, Molecular Cancer Therapeutics.

Applications of a 7-day Caco-2 cell model in drug discovery and development.

A. Railkar, Preeti Yadava, N. Parrott, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.

Alam Jahangir, Johannes C. Hermann, Seth Harris, 2013, Journal of medicinal chemistry.

Preclinical evaluation of the novel multi-targeted agent R1530

D. Carvajal, A. Railkar, P. Wovkulich, 2011, Cancer Chemotherapy and Pharmacology.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors.

Johannes C. Hermann, John Menke, A. Kuglstatter, 2013, Journal of medicinal chemistry.